You are here

  • Home
  • Archive
  • Volume 6, Issue 5
  • Assessing vaccine introduction and uptake timelines in Gavi-supported countries: are introduction timelines accelerating across vaccine delivery platforms?

Article info

Article menu
XML
Original research
Assessing vaccine introduction and uptake timelines in Gavi-supported countries: are introduction timelines accelerating across vaccine delivery platforms?

Authors

  • Karuna Luthra International Vaccine Access Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USAVaccines & Sustainability, GAVI Alliance, Geneva, Geneva, Switzerland PubMed articlesGoogle scholar articles
  • Anna Zimmermann Jin (Formerly Applied Strategies), Strategic Decisions Group, Palo Alto, California, USASkoll Foundation, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • Prarthana Vasudevan International Vaccine Access Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USACenter for Health Security, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Karen Kirk International Vaccine Access Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USAESS, Cherry Hill, New Jersey, USA PubMed articlesGoogle scholar articles
  • Carol Marzetta (Formerly Applied Strategies), Strategic Decisions Group, Palo Alto, California, USA PubMed articlesGoogle scholar articles
  • Lois Privor-Dumm International Vaccine Access Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USAInternational Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Lois Privor-Dumm; lprivor1{at}jhu.edu
View Full Text

Citation

Luthra K, Zimmermann Jin A, Vasudevan P, et al
Assessing vaccine introduction and uptake timelines in Gavi-supported countries: are introduction timelines accelerating across vaccine delivery platforms?
BMJ Global Health 2021;6:e005032.

Publication history

  • Received January 16, 2021
  • Revised May 1, 2021
  • Accepted May 3, 2021
  • First published May 27, 2021.
Online issue publication 
January 12, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.